TuisMOLN • NASDAQ
add
Molecular Partners AG
Vorige sluiting
$4,48
Jaarwisseling
$3,36 - $5,91
Markkapitalisasie
171,13 m USD
Gemiddelde volume
8,12 k
P/V-verhouding
-
Dividend-opbrengs
-
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (CHF) | Sep. 2025info | J/J-verandering |
|---|---|---|
Inkomste | — | — |
Bedryfskoste | 3,60 m | -18,25% |
Netto inkomste | -11,84 m | 27,85% |
Netto winsgrens | — | — |
Wins per aandeel | -0,33 | 32,65% |
EBITDA | -11,40 m | 18,54% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (CHF) | Sep. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 104,52 m | -27,22% |
Totale bates | 112,15 m | -27,27% |
Totale aanspreeklikheid | 16,62 m | 7,70% |
Totale ekwiteit | 95,53 m | — |
Uitstaande aandele | 37,40 m | — |
Prys om te bespreek | 1,76 | — |
Opbrengs op bates | -25,23% | — |
Opbrengs op kapitaal | -29,02% | — |
Kontantvloei
Netto kontantverandering
| (CHF) | Sep. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -11,84 m | 27,85% |
Kontant van bedrywe | -9,93 m | 25,27% |
Kontant van beleggings | 10,66 m | -25,01% |
Kontant van finansiering | -304,00 k | -1,00% |
Netto kontantverandering | 384,00 k | 481,82% |
Beskikbare kontantvloei | -5,40 m | 33,24% |
Meer oor
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Gestig
2004
Webwerf
Werknemers
153
